Interventional device developer Ethicon Endo-Surgery (EES) of Cincinnati has received an offer from Devicor Medical Products of Pleasant Prairie, WI, to acquire EES' Breast Care business.
In announcing the proposed divestiture, Ethicon Endo-Surgery said that after a strategic review, the company had determined that the Breast Care business was outside the scope of its "future growth platforms," and it had decided to explore the sale of the business.
Under the proposed deal, Devicor would acquire the entire product portfolio that is sold in more than 38 countries worldwide and includes the Mammotome breast biopsy system and tissue markers (MammoMark, MicroMark, and CoreMark) used for breast disease diagnostic sampling and management. Financial terms of the offer were not disclosed.
Additionally, the EES Breast Care business would transfer its marketing and distribution rights for the Neoprobe gamma detection systems to Devicor.
The acceptance period for the offer will end on June 15, unless extended. If the offer is accepted by EES, the proposed transaction will be subject to certain conditions and could close by the third quarter.
Related Reading
Hologic, Ethicon bury the hatchet, February 22, 2010
Ethicon to acquire SurgRx, August 12, 2008
Ethicon unveils new MR biopsy system, June 15, 2007
Road to RSNA, Ethicon Endo-Surgery, November 9, 2007
MR mammo alters treatment course: A case study, October 19, 2007
Copyright © 2010 AuntMinnie.com
